Trump’s Pick For HHS Draws Democrats’ Scrutiny Over Health Care Stock Trading
Senate Democrats call for a delay in the confirmation hearings for Rep. Tom Price, R-Ga., who has been tapped by President-elect Donald Trump to head the Department of Health and Human Services. Democrats want to investigate trades he made while handling legislation in Congress that could impact the value of those shares.
Reuters:
Democrats Demand Probe Of Trump Health Nominee
Senate Democrats on Thursday demanded an ethics probe into Tom Price, President-elect Donald Trump's pick for U.S. health secretary, following a report that the fierce Obamacare critic traded in healthcare company stocks while pushing legislation in Congress that could affect those shares. Senate Democratic leader Chuck Schumer and others made their comments as congressional Republicans moved ahead with their long-desired effort to dismantle President Barack Obama's Affordable Care Act, and signaled the vehemence with which Democrats will fight to protect the 2010 law. (Cornwell and Heavey, 1/5)
In other Trump administration news —
Modern Healthcare:
Trump Vets Former Henry Ford CEO Nancy Schlichting For VA Post
Nancy Schlichting, the recently retired CEO of the Henry Ford Health System who last year chaired a commission tasked with finding ways to revamp the Veteran Affairs Department's health system, Thursday met with the Trump transition team in New York. President-elect Donald Trump is considering her for a post he's had trouble filling— VA secretary. Cleveland Clinic CEO Toby Cosgrove withdrew from consideration for that post earlier this week. Luis Quinonez, the other rumored pick, reportedly backed out over the weekend. Quinonez is the president of MAQ Diversified, a Virginia-based physician staffing company. (Barkholz, 1/5)
The Wall Street Journal:
Trump Defense Nominee James Mattis Resigns From Theranos Board
The retired Marine Corps general President-elect Donald Trump has picked to lead the Defense Department resigned from the board of embattled Theranos Inc., people familiar with the matter said. The move distances Gen. James Mattis from a blood-testing startup embroiled in scandal ahead of his confirmation hearings. (Weaver, 1/5)